Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 562-569

  Touw, D J ^a   Vinks, A A T M M ^b   Jacobs, F ^c   Heijerman, H G M ^c   Bakker, W ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Hague Hospitals Central Pharmacy   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Creatinine clearance; Cystic fibrosis; Elimination rate constant; Pharmacokinetics; Tobramycin clearance

Indexed keywords

CREATININE; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; CYSTIC FIBROSIS; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; ANTI-BACTERIAL AGENTS; CREATININE; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; TOBRAMYCIN;

EID: 0029740379     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00007     Document Type: Article

References (20)

1. De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: Difference and clinical significance. Clin Pharmacokinet 1987;13:228-53.
2. MacDonald NE, Anas N, Peterson RG, Schwartz RH, Brooks JG, Powell KR. Renal clearance of gentamicin in cystic fibrosis. J Pediatr 1983;103:985-9.
3. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-24.
4. Reference removed from proof.
5. Hsu M-C, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis 1984;3:526-9.
6. Horrevorts AM, Witte J de, Degener JE, et al. Tobramycin in patients with cystic fibrosis: adjustment in dosing interval for effective treatment. Chest 1987;92:844-8.
7. Thomassen MJ, Demko CA, Doershuk CF. Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr Pulmonol 1987;3:334-51.
8. Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985;1:238-43.
9. Touw DJ, Vinks AATMM, Heijerman HGM, Hermans J, Bakker W. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1994;16:125-31.
10. Kildoo CW, Harralson AF, Folli HL, Kelly PC, Nussbaum E. Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis. Drug Intell Clin Pharm 1987;21:639-41.
11. Touw DJ, Vinks AATMM, Heijerman HGM, Bakker W. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1993;15:52-9.
12. Jelliffe RW. Creatinine clearance: a bedside estimate. Ann Intern Med 1973;79:604-5.
13. Jelliffe RW, Jelliffe SM. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex and weight. Math Biosci 1987;14:17-24.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-12.
16. Hedman A, Adan-Abdi Y, Alvan G, Strandvik B, Arvidsson A. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet 1988;15:57-65.
17. Hedman A, Alvan G, Strandvik B, Arvidsson A. Increased renal clearance of cefsolodin due to higher glomerular filtration rate in cystic fibrosis. Clin Pharmacokinet 1990;18:168-75.
18. Contrepois A, Brion N, Garaud JJ, et al. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother 1985; 27:520-4.
19. Ng PK. Determining aminoglycoside dosage and blood levels using a programmable calculator. Am J Hosp Pharm 1980; 37:225-31.
20. Echizen H, Ishizaki T. Superiority of disease-specific over conventional formula in predicting creatinine clearance from serum creatinine in patients with liver cirrhosis. Ther Drug Monit 1988;10:369-75.